KR20060127992A - 급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도 - Google Patents

급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도 Download PDF

Info

Publication number
KR20060127992A
KR20060127992A KR1020067016937A KR20067016937A KR20060127992A KR 20060127992 A KR20060127992 A KR 20060127992A KR 1020067016937 A KR1020067016937 A KR 1020067016937A KR 20067016937 A KR20067016937 A KR 20067016937A KR 20060127992 A KR20060127992 A KR 20060127992A
Authority
KR
South Korea
Prior art keywords
atiii
lung injury
protein
antithrombin iii
antithrombin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020067016937A
Other languages
English (en)
Korean (ko)
Inventor
가즈노리 무라카미
페렌레이 엔크바아타르
로버트 에이 콕스
할 에이 호킨스
릴리안 디 트라버
다니엘 엘 트라버
Original Assignee
지티씨바이오쎄라퓨틱스,인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지티씨바이오쎄라퓨틱스,인크. filed Critical 지티씨바이오쎄라퓨틱스,인크.
Publication of KR20060127992A publication Critical patent/KR20060127992A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020067016937A 2004-01-23 2005-01-14 급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도 Abandoned KR20060127992A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53867804P 2004-01-23 2004-01-23
US60/538,678 2004-01-23
US11/034,590 2005-01-13
US11/034,590 US20050169908A1 (en) 2004-01-23 2005-01-13 Use of aerosolized antithrombin to treat acute lung injury

Publications (1)

Publication Number Publication Date
KR20060127992A true KR20060127992A (ko) 2006-12-13

Family

ID=34810485

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067016937A Abandoned KR20060127992A (ko) 2004-01-23 2005-01-14 급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도

Country Status (8)

Country Link
US (1) US20050169908A1 (enExample)
EP (1) EP1713500A2 (enExample)
JP (1) JP4854519B2 (enExample)
KR (1) KR20060127992A (enExample)
AU (1) AU2005208552A1 (enExample)
CA (1) CA2553758A1 (enExample)
IL (1) IL177028A0 (enExample)
WO (1) WO2005072139A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535487A (en) * 2002-04-01 2008-12-24 Univ Texas Medical Branch Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
WO2014089327A1 (en) * 2012-12-05 2014-06-12 National Jewish Health Treatment for airway cast obstruction
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
ES2793176T3 (es) 2013-07-05 2020-11-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Matriz de cromografía de afinidad
CA2928759A1 (en) 2013-11-04 2015-05-07 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
WO2016179447A1 (en) * 2015-05-06 2016-11-10 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
NZ535487A (en) * 2002-04-01 2008-12-24 Univ Texas Medical Branch Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Also Published As

Publication number Publication date
JP2007518801A (ja) 2007-07-12
US20050169908A1 (en) 2005-08-04
IL177028A0 (en) 2006-12-10
WO2005072139A2 (en) 2005-08-11
CA2553758A1 (en) 2005-08-11
WO2005072139A3 (en) 2006-01-05
AU2005208552A1 (en) 2005-08-11
EP1713500A2 (en) 2006-10-25
JP4854519B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
US20110070167A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
EP0971724B1 (en) Expression of active human factor ix in mammary tissue of transgenic animals
US7642234B2 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
KR20060127992A (ko) 급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도
JP2003521914A (ja) トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
JP2021519819A (ja) 同所性及び異所性異種心臓、腎臓、肺又は肝臓移植後の生存を延長するための方法及び組成物
US20080004212A1 (en) Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
EP1390407B1 (en) The lectin-like domain of thrombomodulin and its therapeutic use
JPH10508756A (ja) 造血タンパク質を用いて赤血球形成を刺激する方法
Turner Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies
US20050245444A1 (en) Method of using recombinant human antithrombin for neurocognitive disorders
KR102772403B1 (ko) 알파-1 안티 트립신 결핍증 z 타입 돌연변이의 교정을 위한 프라임에디팅 가이드 rna를 포함하는 프라임에딩팅용 조성물
AU2011202575A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
CN1946419A (zh) 使用气溶胶化抗凝血酶治疗急性肺损伤
US20110294733A1 (en) Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
AU2002312938B2 (en) The lectin-like domain of thrombomodulin and its therapeutic use
JP2017506676A (ja) Ｃ１阻害剤を用いる遺伝性血管性浮腫の治療
Shaposhnik The roles of granulocyte-macrophage colony stimulating factor and macrophage colony stimulating factor in atherosclerosis
JP2004208662A (ja) Ｌｏｘ−１遺伝子欠損動物
AU2002312938A1 (en) The lectin-like domain of thrombomodulin and its therapeutic use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060823

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100113

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20110707

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110718

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120308

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee